Literature DB >> 30714387

How Leading Hospitals Operationalize Evidence-Based Readmission Reduction Strategies: A Mixed-Methods Comparative Study Using Systematic Review and Survey Design.

Bita A Kash1,2, Juha Baek1,2, Ohbet Cheon2, Joanna-Grace Mayo Manzano3, Stephen L Jones2, Jaya Paranilam2, Robert A Phillips2.   

Abstract

Although various interventions targeted at reducing hospital readmissions have been identified in the literature, little is known about actual operationalization of such evidence-based interventions. This study conducted a systematic review and a survey of key informants in 2 leading hospitals, Houston Methodist (HM) and MD Anderson Cancer Center (MDACC), to compare and contrast the most cited evidence-based interventions in the current literature with interventions reported by those hospitals. The authors found that both hospitals followed evidence-based practices reported as successful in the literature. Both hospitals have implemented interventions for inpatient settings, and the timing of interventions was very similar. Major implementation differences observed for post-discharge interventions focused on collaboration. It also was found that HM was more likely than MDACC to use medication reconciliation in outpatient (P = .018) and discharge planning for community/home patients (P = .032). Results will provide hospital professionals with insights for implementing the most effective interventions to reduce readmissions.

Entities:  

Keywords:  comparative study; evidence-based interventions; hospital readmissions; survey

Mesh:

Year:  2019        PMID: 30714387     DOI: 10.1177/1062860618824410

Source DB:  PubMed          Journal:  Am J Med Qual        ISSN: 1062-8606            Impact factor:   1.852


  1 in total

1.  One Quarter of Medicare Hospitalizations in Patients with Systemic Lupus Erythematosus Readmitted within Thirty Days.

Authors:  Christie M Bartels; Ann Chodara; Yi Chen; Xing Wang; W Ryan Powell; Fangfang Shi; Maria Schletzbaum; Ann M Sheehy; Farah A Kaiksow; Andrea L Gilmore-Bykovskyi; Shivani Garg; Menggang Yu; Amy J Kind
Journal:  Semin Arthritis Rheum       Date:  2021-02-19       Impact factor: 5.431

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.